AstraZeneca, Amgen Announce Positive Phase III Brodalumab Study

By Dow Jones Business News, 
A A A


By Razak Musah Baba

LONDON--AstraZeneca PLC (AZN.LN) and Amgen Inc. ( AMGN ) said Monday that the Phase III AMAGINE-1 study evaluating brodalumab in patients with moderate-to-severe plaque psoriasis met all primary and secondary endpoints for both evaluated doses.

The companies said a significantly higher proportion of patients treated with brodalumab achieved a PASI 75 response, or primary endpoint, as well as PASI 90 and PASI 100 responses at week 12, secondary endpoints, compared to a placebo.

"Data from the AMAGINE-1 study suggest that brodalumab may offer a new level of efficacy for patients with moderate- to-severe plaque psoriasis, a disease that affects more than 100 million people globally," said Sean E. Harper, executive vice president of research and development at Amgen.

"Moderate-to-severe plaque psoriasis is a serious disease, and despite available treatments, there is still a significant need for more effective therapies," Briggs Morrison, executive vice president of global medicines development at AstraZeneca, added.

Write to Razak Musah Baba at razak.baba@wsj.com; Twitter: @Raztweet

Subscribe to WSJ: http://online.wsj.com?mod=djnwires


  (END) Dow Jones Newswires
  05-12-140239ET
  Copyright (c) 2014 Dow Jones & Company, Inc.


This article appears in: News Headlines

Referenced Stocks: AMGN

Dow Jones Business News


More from Dow Jones Business News:

Related Videos

Stocks

Referenced

100%

Most Active by Volume

54,168,351
  • $6.895 ▲ 16.08%
51,723,945
  • $12.501 ▲ 18.72%
48,924,206
  • $3.399 ▲ 0.56%
41,961,842
  • $36.855 ▲ 3.38%
28,856,383
  • $40.94 ▲ 8.57%
23,245,340
  • $6.495 ▼ 2.91%
17,827,832
  • $98.43 ▼ 0.60%
14,408,297
  • $15.43 ▼ 0.45%
As of 7/29/2014, 11:09 AM